NASDAQ:ZGNX Zogenix (ZGNX) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free ZGNX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$26.68▼$26.6850-Day Range$26.10▼$26.6852-Week Range$11.03▼$26.90Volume94 shsAverage Volume3.76 million shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zogenix alerts: Email Address Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Zogenix Stock (NASDAQ:ZGNX)Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.Read More Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. ZGNX Stock News HeadlinesMarch 23, 2024 | morningstar.comHwasung Industrial Co Ltd 002460July 6, 2023 | fool.comAlcon (NYSE: ALC)May 3, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.May 21, 2023 | morningstar.comLongeveron Inc Ordinary Shares - Class AOctober 11, 2022 | businesswire.comHow Women Lead #GetonBoard Week Honorees Are Helping Catapult Fearless Women Leaders into Board Seats - Business WireSeptember 30, 2022 | forbes.comBiocryst PharmaceuticalsSeptember 26, 2022 | marketscreener.comNippon Shinyaku : Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome - Marketscreener.comSeptember 13, 2022 | marketscreener.comPROMIS NEUROSCIENCES INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.comMay 3, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.September 10, 2022 | bizjournals.comHow Women Lead appoints three new executive board members - Bizwomen - The Business JournalsSeptember 9, 2022 | bizjournals.comEast Bay Biotech Companies - San Francisco Business Times - The Business JournalsSeptember 9, 2022 | prnewswire.comOncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - PR NewswireSeptember 8, 2022 | streetinsider.comOncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - StreetInsider.comSeptember 7, 2022 | finance.yahoo.comOncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - Yahoo FinanceAugust 30, 2022 | bizjournals.comWith early-cancer detection technology, Delfi Diagnostics looks to beat out Guardant Health, Illumina's Grail and others - San Francisco Business Times - The Business JournalsAugust 29, 2022 | thestreet.comDepomed Reports Dip in Earnings, Reduces Revenue GuidanceAugust 23, 2022 | prnewswire.comDelfi Diagnostics Adds Finance and Market Access Leadership as It Prepares for Commercial Launch - PR NewswireAugust 16, 2022 | businesswire.comNuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer - Business WireAugust 15, 2022 | streetinsider.comNuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer - StreetInsider.comAugust 9, 2022 | businesswire.comDravet Syndrome Treatment Market Report 2022-2029: Stiripentol and Cannabidiol to Contribute to Significant Growth of 11.7% - ResearchAndMarkets.com - Business WireAugust 3, 2022 | streetinsider.comTevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board - StreetInsider.comAugust 2, 2022 | prnewswire.comGeno Hires First Chief Legal Officer on Path to Accelerate the Transition to More Sustainable Materials - PR NewswireJuly 28, 2022 | marketscreener.comUCB : Strong first six months – UCB with continued delivery and strong resilience - Marketscreener.comJune 25, 2022 | gurufocus.comAdamis Appoints Vickie Reed to Board of Directors - GuruFocus.comJune 24, 2022 | marketscreener.comUCB : updates financial guidance for 2022 while maintaining 2025 financial guidance - Marketscreener.comJune 8, 2022 | businesswire.comADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology - Business WireJune 8, 2022 | seekingalpha.comUCB's therapy gets FDA orphan drug status to treat seizures linked with rare epilepsy - Seeking AlphaSee More Headlines Receive ZGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZGNX CUSIP98978L10 CIK1375151 Webwww.zogenix.com Phone(510) 550-8300Fax858-259-1166Employees218Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,380,000.00 Net Margins-278.38% Pretax Margin-278.26% Return on Equity-91.20% Return on Assets-43.60% Debt Debt-to-Equity Ratio0.88 Current Ratio3.63 Quick Ratio4.74 Sales & Book Value Annual Sales$81.69 million Price / Sales18.36 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book4.02Miscellaneous Outstanding Shares56,227,000Free Float53,922,000Market Cap$1.50 billion OptionableOptionable Beta0.89 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesStephen James FarrPresident, Chief Executive Officer & DirectorAshish M. SagrolikarChief Operating Officer & Executive Vice PresidentMichael Patrick SmithChief Financial Officer, Treasurer & Executive VPBradley S. GalerChief Medical Officer & Executive Vice PresidentSteven A. JohnsonVice President, Legal Council & Compliance OfficeKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNPacira BioSciencesNASDAQ:PCRXORIC PharmaceuticalsNASDAQ:ORICStoke TherapeuticsNASDAQ:STOKCorcept TherapeuticsNASDAQ:CORTView All Competitors ZGNX Stock Analysis - Frequently Asked Questions How were Zogenix's earnings last quarter? Zogenix, Inc. (NASDAQ:ZGNX) released its earnings results on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.08. The firm earned $22.61 million during the quarter, compared to the consensus estimate of $22.71 million. Zogenix had a negative trailing twelve-month return on equity of 91.20% and a negative net margin of 278.38%. The business's quarterly revenue was up 690.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.02) EPS. What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO? 7 employees have rated Zogenix Chief Executive Officer Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among the company's employees. What other stocks do shareholders of Zogenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU). This page (NASDAQ:ZGNX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldFW: 234x GainWeiss RatingsUrgent Nvidia WarningAltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupCould Your Accounts Be Frozen?Allegiance GoldDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
